Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous; 20 mg) |
| Drug Class | Hydrolytic lysosomal enzymes |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xenpozyme (olipudase alfa-rpcp) prescribing information. | 2023 | Genzyme Corporation, Cambridge, MA |